JS Link Inc, formerly DNA Link Inc, is a Korea-based company mainly engaged in the genome analysis business. The Company mainly engages in the research and development of genome analysis services and personal genome analysis service products used for disease prevention, diagnosis, and treatment. The Company also mainly engages in the manufacture and sale of coronavirus disease 2019 (COVID-19) diagnostic kits. In addition, the Company engages in the research and development of â€˜Avatar Mouse,â€™ an anticancer drug efficacy evaluation system using the mouseâ€™s biological system.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
21/08/26	KRW 34,000.00	-8.72%	209,336
20/08/26	KRW 37,250.00	+1.50%	83,321
19/08/26	KRW 36,700.00	-3.55%	212,847
18/08/26	KRW 38,050.00	-6.05%	263,606

End-of-day quote Korea S.E.

More quotes

End-of-day quote Korea S.E. 21/08/2026			5-day change	1st Jan Change
34,000.00 ^KRW	-8.72%		-16.05%	+90.48%

29/07	JS Link, Inc. announced that it has received KRW 53.392992 billion in funding from Lynas Rare Earths Limited	CI
08/07	REalloys Inc. and JS Link Inc. Sign Non-Binding Strategic Letter of Intent to Develop Fully Integrated North American Rare Earth Magnet Platform	CI

Market Cap	1,182B 853M 730M 683M 626M 1.17B 81.57B 1.19B 8.07B 3.15B 40.98B 3.2B 3.13B 136B	P/E 2024	-10.5x	P/E 2025	-29.7x
Enterprise Value	1,184B 855M 732M 685M 627M 1.18B 81.77B 1.19B 8.09B 3.16B 41.08B 3.21B 3.14B 136B	EV / Sales 2024	8.93x	EV / Sales 2025	29.6x
Free-Float	71.99%	Yield 2024 *	-	Yield 2025	-

29/07	JS Link, Inc. announced that it has received KRW 53.392992 billion in funding from Lynas Rare Earths Limited	CI
08/07	REalloys Inc. and JS Link Inc. Sign Non-Binding Strategic Letter of Intent to Develop Fully Integrated North American Rare Earth Magnet Platform	CI
07/07	Australia's Lynas, South Korea's JS Link sign deal for Malaysia magnet factory	RE
07/07	Australia's Lynas signs deal with South Korea's JS Link to develop Malaysian magnet factory	RE
25/06	JS Link, Inc. announced that it has received KRW 30 billion in funding from Joosung Sea & Air Co. Ltd	CI
15/05	JS Link, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
13/05	JS Link, Inc. announced that it expects to receive KRW 5 billion in funding	CI
13/05	JS Link, Inc. announced that it expects to receive KRW 30 billion in funding	CI
23/03	JS Link, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
03/02	JS Link, Inc. announced that it has received KRW 20.00000805 billion in funding from Orbitech Co., Ltd., Joosung Sea & Air Co. Ltd	CI
14/11	JS Link, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
03/11	Malaysia PM says $142 million magnet plant to boost rare earth sector, state media reports	RE
29/10/25	JS Link, Inc. announced that it has received KRW 20.000005568 billion in funding from B & P Joosung Corp.	CI

1 day	-8.72%
1 week	-16.05%
Current month	+17.44%
1 month	-2.72%
3 months	-13.71%
6 months	-8.85%
Current year	+90.48%

JS Link, Inc. Stock

Stocks

A127120

KR7127120004

Biotechnology & Medical Research

Valuation: JS Link, Inc.

Chart: JS Link, Inc.

Latest news : JS Link, Inc.

Press Releases: JS Link, Inc.

Quotes and Performance

Course Extremes

Managers and Directors: JS Link, Inc.

Latest insider transactions

Other Biotechnology & Medical Research

Financials

Company Profile

Quotes

1 week	33,700	41,400
1 month	26,400	43,500
Current year	16,230	49,900
1 year	13,860	49,900
3 years	1,775	49,900
5 years	1,775	49,900
10 years	1,775	49,900

Manager	Title	Age	Since
Jun-Young Lee CEO	Chief Executive Officer	58	23/08/2024
Cheol-Gu Sim CEO	Chief Executive Officer	47	20/10/2023
Kenji Gonishi PRN	Corporate Officer/Principal	58	23/08/2024

Director	Title	Age	Since
Cheol-Gu Sim BRD	Director/Board Member	47	20/10/2023
Jun-Young Lee BRD	Director/Board Member	58	23/08/2024
Kenji Gonishi BRD	Director/Board Member	58	23/08/2024

Date	Insider	Type	Quantity	% Market Cap.
19/11/25	Jin-soo Park	Buy	1,500	0.0047%
17/11/25	Jin-soo Park	Buy	5,000	0.0157%
4/11/25	Jin-soo Park	Buy	87,138	0.2742%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
JS LINK, INC.	-8.72%	-16.05%	+98.14%	+860.45%	853M
LONZA GROUP AG	+1.09%	+5.26%	+4.52%	+23.38%	51.61B
REVOLUTION MEDICINES, INC.	-1.07%	+2.82%	+465.96%	+570.70%	44.89B
IQVIA HOLDINGS INC.	+1.47%	+9.79%	+35.92%	+20.21%	42.77B
BEONE MEDICINES AG	+1.44%	+7.77%	+19.38%	+84.65%	42.58B
CELLTRION, INC.	-0.93%	-4.33%	+16.18%	+55.82%	31.82B
MEDPACE HOLDINGS, INC.	+1.32%	+7.30%	+33.89%	+148.53%	17.33B
ASCENDIS PHARMA A/S	-0.60%	+1.93%	-	-	16.63B
EUROFINS SCIENTIFIC SE	+0.03%	+3.41%	+6.55%	+29.84%	14.76B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	+1.28%	+5.41%	+82.40%	+46.13%	14.09B
Average	-0.47%	+2.39%	+84.77%	+204.41%	27.73B
Weighted average by Cap.	+0.46%	+4.65%	+99.57%	+143.73%

	2024	2025
Net sales	15.91B 11.48M 9.83M 9.2M 8.42M 15.8M 1.1B 16.01M 109M 42.39M 552M 43.1M 42.16M 1.82B	19.32B 13.94M 11.94M 11.17M 10.23M 19.19M 1.33B 19.44M 132M 51.47M 670M 52.34M 51.2M 2.22B
Net income	-10.8B -7.79M -6.68M -6.25M -5.72M -10.73M -746M -10.87M -73.81M -28.78M -375M -29.27M -28.63M -1.24B	-16.45B -11.87M -10.16M -9.51M -8.71M -16.34M -1.14B -16.55M -112M -43.82M -570M -44.56M -43.59M -1.89B
Net Debt	14.39B 10.38M 8.9M 8.32M 7.62M 14.3M 994M 14.49M 98.34M 38.35M 499M 38.99M 38.15M 1.65B	2.88B 2.08M 1.78M 1.67M 1.53M 2.86M 199M 2.9M 19.69M 7.68M 99.93M 7.81M 7.64M 331M